Viracta Therapeutics Inc Ordinary Shares VIRX 深 沪
已收盘 09-18 16:00:00 美东时间
0.2195
0.000
-0.23%
华盛通- 最 高0.22
- 今 开0.2134
- 成交量 46.67万股
- 最 低 0.2101
- 昨 收 0.22
- 总市值 846.84万
- 52周最高 1.31
- 市盈率 静 --
- 换手率 1.21%
- 52周最低 0.202
- 委 比 -23.60%
- 总股本 3858.04万
- 历史最高 1775.55
- 量 比 2.00
- 振 幅 4.50%
- 历史最低 0.202
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多快讯 | Viracta Therapeutics Inc：Leerink合作伙伴将目标价从5美元下调至3美元，将其评级从跑赢大盘降至市场表现。
Viracta Therapeutics Inc : Leerink Partners Cuts to Market Perform From Outperf...
08-16 13:51
RBC Capital Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $4
RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target from $6 to $4.
08-15 22:55
快讯 | Viracta Therapeutics公司：瑞银将目标价从6美元下调至4美元
Viracta Therapeutics Inc : RBC Cuts Target Price to $4 From $6
08-15 14:11
Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?
Viracta Therapeutics stock gains after Phase 2 NAVAL-1 trial results for relapsed or refractory EBV+ PTCL cohort. The company plans pipeline reprioritization and a reduction in force.
08-14 21:19
Viracta Therapeutics Announces Key Business Developments
An announcement from Viracta Therapeutics (VIRX) is now available. On August 14...
08-14 19:53
Viracta jumps after corporate update
Nanocap biotech Viracta Therapeutics (NASDAQ:VIRX) added ~20% premarket Wednesday after the company announced a corporate shake-up to prioritize its Epstein-Barr virus-positive (EBV+) lymphoma program...
08-14 19:49
快讯 | Viracta Therapeutics第二季度净利润为美元指数-980万。
Viracta Therapeutics Q2 Net Income USD -9.8 Million
08-14 19:05
快讯 | Viracta Therapeutics报告了2024年第二季度的财务业绩，并提供了业务更新
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides...
08-14 19:05
快讯 | Viracta Therapeutics宣布海军-1期试验获得积极数据，监管进展及Nana-Val临床发展计划更新。
Viracta Therapeutics Announces Positive Data From the Phase 2 Naval-1 Trial, Re...
08-14 19:00
